Advertisement
Screener

SAREPTA THERAPEUTICS, INC. (SRPT) Increase (Decrease) in Accounts Receivable and Other Operating Assets

2.8 / 5 stars · 68/120 Roast Me

SAREPTA THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable and Other Operating Assets

SAREPTA THERAPEUTICS, INC. (SRPT) reported Increase (Decrease) in Accounts Receivable and Other Operating Assets of $20.96 million for the 6-month period ending 2014-06-30, per its 10-Q filed 2014-08-07.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets · last filed 2014-08-07

  • SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2014-06-30 was $10.62M.
  • SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2014-03-31 was $10.34M, a 777.50% increase year-over-year.
  • SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2013-12-31 was -$3.32M, a 236.95% decline year-over-year.
  • SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2013-09-30 was $1.07M.
  • SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for fiscal 2013 was -$2.80M, a 178.09% decline from fiscal 2012.
  • SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for fiscal 2012 was $3.59M, a 237.44% increase from fiscal 2011.
  • SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for fiscal 2011 was $1.06M.
Period endIncrease (Decrease) in Accounts Receivable and Other Operating Assets 3 monthIncrease (Decrease) in Accounts Receivable and Other Operating Assets 6 monthIncrease (Decrease) in Accounts Receivable and Other Operating Assets 9 monthIncrease (Decrease) in Accounts Receivable and Other Operating Assets 12 monthIncrease (Decrease) in Accounts Receivable and Other Operating Assets 395 monthIncrease (Decrease) in Accounts Receivable and Other Operating Assets 398 monthIncrease (Decrease) in Accounts Receivable and Other Operating Assets 401 monthIncrease (Decrease) in Accounts Receivable and Other Operating Assets 404 month
2014-06-30$10.62M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
$20.96M
10-Q · filed 2014-08-07
$17.64M
derived: sum of 3 quarters · filed 2014-08-07
$18.70M
derived: sum of 4 quarters · filed 2014-08-07
2014-03-31$10.34M
10-Q · filed 2014-05-08
$7.02M
derived: sum of 2 quarters · filed 2014-05-08
$8.09M
derived: sum of 3 quarters · filed 2014-05-08
$6.36M
derived: sum of 4 quarters · filed 2014-08-07
$16.30M
10-Q · filed 2014-05-08
2013-12-31-$3.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
-$2.25M
derived: sum of 2 quarters · filed 2014-03-03
-$3.98M
derived: sum of 3 quarters · filed 2014-08-07
-$2.80M
10-K · filed 2014-03-03
$5.96M
10-K · filed 2014-03-03
2013-09-30$1.07M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
-$658.00K
derived: sum of 2 quarters · filed 2014-08-07
$520.00K
10-Q · filed 2013-11-12
$2.94M
derived: sum of 4 quarters · filed 2014-08-07
$9.28M
10-Q · filed 2013-11-12
2013-06-30-$1.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
-$549.00K
10-Q · filed 2014-08-07
$1.88M
derived: sum of 3 quarters · filed 2014-08-07
-$499.00K
derived: sum of 4 quarters · filed 2014-08-07
$8.21M
10-Q · filed 2013-08-08
2013-03-31$1.18M
10-Q · filed 2014-05-08
$3.60M
derived: sum of 2 quarters · filed 2014-05-08
$1.23M
derived: sum of 3 quarters · filed 2014-05-08
2012-12-31$2.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
$50.00K
derived: sum of 2 quarters · filed 2014-03-03
$3.59M
10-K · filed 2014-03-03
2012-09-30-$2.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
$1.16M
10-Q · filed 2013-11-12
2012-06-30$3.54M
10-Q · filed 2013-08-08
2011-12-31$1.06M
10-K · filed 2014-03-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
UroGen Pharma Ltd. (URGN)$2.015B-18.42
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
Generate Biomedicines, Inc. (GENB)United States$2.052B
COMPASS Pathways plc (CMPS)$1.812B-4.87
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77